Global study shows blood glucose levels dropped significantly, and low rates of low blood sugar
But blood cancer experts call for more research
Doctors expect this will become new standard for people with mantle-cell lymphoma
Women are also underrepresented, researchers find
'Breakthroughs' are rare, so view bold claims with skepticism, researcher warns
Next step is to see if it works and for how long
Findings were so dismal that clinical trial was stopped early
Doctors should weigh risks, benefits related to corticosteroid use, study suggests
With tocilizumab's approval, there's an alternative treatment for giant cell arteritis
If findings replicated, a shot every month or two could replace daily pills, scientists say
Affordable Care Act changed rules for private insurers
Last new drug for the memory-robbing disease was introduced in the United States in 2003
A mouse study shows the vaccines protected unborn baby mice from the virus
New product much easier to use than rescue injections, researcher says
Researchers hope it will prove as effective in human tests and become an aid for recovering addicts
Study looked at data stretching from 1956 and 2016
Medications show promise for non-small cell type
Lynparza may offer a new treatment for women with advanced BRCA-related disease, researchers say
But the gene flaw is rare, affecting less than 1 percent of typical cancers, researchers say
Findings could 'change clinical practice overnight,' leading oncologist says
3-drug mixture was nearly 100 percent effective in drug company trials
Small study suggests a new approach might one day help those with uncontrolled lung disease
But treatment isn't yet approved by FDA to treat inflammatory bowel condition
Combo therapy may also extend survival of glioblastoma patients, but more research needed
FDA outlines what to ask before enrollment
Proposal would allow the gravely ill access to experimental therapies that may or may not work
Taking triple the daily recommendation didn't lower risk in older women, but larger trials are underway
Repatha, inclisiran lowered cholesterol levels even further, but first costs about $14,000 a year to take
Review found younger patients fared better over 5 years, though some deaths reported
Zinplava cuts risk of recurrent C. difficile infections by 40 percent
Opicapone, added to standard treatment, appears safe and well-tolerated, researchers say
17 of 24 children with neurofibromatosis type 1 saw improvement, but more study needed
Cimaglermin appears to strengthen cells and improve heart function, researchers report
Specialist hopes ocrelizumab will be available by spring